Skip to main content

IDWeek 2023 Main banner

Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

Back

Vrunda Parikh, PharmD

Vaccine Research and Development, Pfizer Inc

Poster(s):

(362) Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to Toddlers and Children 6 Months to < 5 Years of Age Who Previously Received Original BNT162b2 as a 3-Dose Primary Series

Thursday, October 12, 2023
12:15 PM – 1:30 PM US ET
(385) Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to 5- to 11-Year-Old Children Who Previously Received 3 Doses of Original BNT162b2

Thursday, October 12, 2023
12:15 PM – 1:30 PM US ET